Basic Clinical Radiobiology 2017

CHHiP-trial • 74 Gy / 2 Gy (37#) vs 60 Gy / 3 Gy (20#) vs 57 Gy / 3 Gy (19#) • 3152 analysable patients • 73% Intermediate risk; 15% Low risk; 12% High risk (NCCN) • 97% Androgen deprivation (3-6 months) • IMRT • Non-inferior design (bNED or cNED -free survival ± 5% at 5 years)

Dearnaley et al. Lancet Oncol. 2016